Scandium

Dosage for Scandium is not standardized in the same way as traditional medications like antibiotics or blood pressure pills. Instead, dosing is highly individualized based on the specific diagnostic procedure or test being performed.

• For Diagnostic Tracing: Doses are typically calculated based on the required level of detection and the patient's body surface area. A common range for tracer studies involves microgram quantities administered intravenously or orally.
• For Allergen Testing: In patch testing, a standardized concentration (often 1% in petrolatum) is applied to a specific area of the skin (usually the back) for a period of 48 to 72 hours.
• For Specialized Imaging: If radioactive isotopes of Scandium are used, the dose is measured in Megabecquerels (MBq) or millicuries (mCi), strictly regulated by nuclear medicine protocols to ensure the lowest possible radiation exposure while achieving clear results.

Scandium is rarely used in pediatric populations unless there is a critical diagnostic need that cannot be met by other means. There are no standardized pediatric doses established by the FDA for Scandium Iodide. If required, dosing is typically weight-based (e.g., mcg/kg) and must be calculated with extreme precision by a pediatric specialist. Healthcare providers will weigh the diagnostic benefits against the potential for long-term accumulation in developing bone tissue.

Renal Impairment

Because the kidneys are the primary route for the elimination of systemic Scandium, patients with impaired renal function (reduced GFR) require significant dosage adjustments. In cases of severe renal failure, the use of Scandium may be contraindicated due to the risk of systemic accumulation and potential toxicity.

Hepatic Impairment

Since Scandium is not metabolized by the liver, dosage adjustments for patients with hepatic impairment are generally not required. However, if the patient has hepatorenal syndrome (liver failure affecting kidney function), the renal precautions must be followed.

Elderly Patients

Geriatric patients often have a natural decline in kidney function. Clinicians typically use the lowest effective dose for diagnostic procedures in patients over 65 and monitor renal clearance closely.

Scandium is almost always administered by a healthcare professional in a clinical setting.

• Intravenous Administration: Will be performed by a nurse or technician. The injection site should be monitored for redness or swelling.
• Oral Administration: If taken as a tracer solution, it should be consumed exactly as directed, often on an empty stomach to ensure consistent (though low) absorption.
• Topical Patch: If undergoing allergy testing, you must keep the patch dry. Do not shower or engage in heavy exercise that causes sweating, as this can dislodge the patch and invalidate the test results.
• Storage: Clinical preparations of Scandium Iodide are stored at controlled room temperature (20°C to 25°C) and protected from light. Radioactive forms require specialized lead-shielded storage.

Since Scandium is typically used for one-time diagnostic procedures or specific testing schedules, a 'missed dose' in the traditional sense is rare. If a diagnostic appointment is missed, it should be rescheduled immediately. If you are on a multi-day testing protocol and miss an appointment, contact your specialist for instructions on how to resume the protocol.

Signs of acute Scandium overdose (toxicity) are rare but may include:

• Nausea and vomiting
• Metallic taste in the mouth
• Acute kidney injury (decreased urine output, swelling in legs)
• Signs of liver stress (yellowing of the skin/eyes)

In the event of a suspected overdose, emergency measures include gastric lavage (if caught early after oral ingestion), intravenous hydration to support renal function, and potentially chelation therapy using agents like EDTA to help remove the metal from the bloodstream.

> Important: Follow your healthcare provider's dosing instructions. Do not adjust your dose or attempt to source Scandium independently without medical guidance.

Most patients tolerate Scandium well, particularly when used in the micro-doses required for diagnostic tracing. However, some common reactions include:

• Injection Site Reactions: Redness, mild swelling, or a 'bruised' feeling at the site where Scandium was injected intravenously. This typically resolves within 24 to 48 hours.
• Metallic Taste: A transient, bitter or metallic taste in the mouth immediately following intravenous administration.
• Mild Nausea: A brief feeling of stomach upset, which usually passes without the need for anti-nausea medication.

• Headache: Mild to moderate tension-type headaches following the procedure.
• Dizziness: A brief sensation of lightheadedness, particularly when standing up quickly after an injection.
• Skin Irritation: In the context of patch testing, localized itching, redness, or small blisters at the site of application are expected as part of a positive test result but may be uncomfortable.

• Hypersensitivity Reactions: Some patients may develop a rash or hives (urticaria) away from the site of administration.
• Gastrointestinal Distress: More significant cramping or diarrhea, particularly after oral tracer doses.
• Hypocalcemia Symptoms: Because Scandium can interfere with calcium binding, extremely high doses could theoretically lead to symptoms of low calcium, such as muscle twitches or tingling in the fingers (though this is clinically rare at diagnostic doses).

> Warning: Stop taking Scandium (if applicable) and call your doctor immediately or seek emergency care if you experience any of the following:

• Anaphylaxis: Signs include difficulty breathing, swelling of the face, lips, or tongue, and a rapid drop in blood pressure. This is a life-threatening emergency.
• Nephrotoxicity: Signs of kidney damage, such as a significant decrease in urine production, blood in the urine, or sudden unexplained weight gain from fluid retention.
• Severe Skin Sloughing: In very rare cases of extreme metal hypersensitivity, a systemic skin reaction could occur.
• Neurological Changes: Confusion, seizures, or extreme tremors, which may indicate systemic toxicity or electrolyte imbalance.

Because Scandium has a high affinity for bone tissue, the primary concern with long-term or repeated exposure is bone accumulation. While the clinical significance of Scandium storage in the bone is not fully understood, it is hypothesized that it could potentially interfere with normal bone remodeling or mineral density over many years. There is also a theoretical risk of lanthanide pneumoconiosis if Scandium dust or vapors are inhaled over long periods (primarily an occupational hazard rather than a medical one).

No FDA black box warnings have been issued for Scandium as of 2026. However, it is regulated under strict protocols for diagnostic agents and radioactive materials. The primary safety focus remains on preventing accidental high-dose exposure and ensuring proper renal function prior to administration.

Report any unusual symptoms to your healthcare provider. You may also report side effects to the FDA at 1-800-FDA-1088.

Scandium should only be administered by trained healthcare professionals in a controlled medical environment. Patients must be screened for pre-existing conditions that might increase the risk of adverse reactions, particularly kidney disease or a history of multiple metal allergies.

There are currently no FDA black box warnings for Scandium. It is considered safe for its intended diagnostic and testing purposes when used according to established clinical protocols.

• Allergic Reactions / Anaphylaxis Risk: While rare, systemic allergic reactions to rare earth metals can occur. Patients with a known history of sensitivity to other metals (like nickel, cobalt, or gadolinium) should be monitored closely during and after administration.
• Nephrotoxicity (Kidney Risk): Scandium is cleared by the kidneys. If kidney function is impaired, the metal can linger in the bloodstream, increasing the risk of systemic toxicity. A serum creatinine test or GFR calculation is often required before systemic administration.
• Bone Deposition: Because Scandium mimics calcium, it can be incorporated into the bone matrix. This is a particular concern for pediatric patients with growing bones and for individuals with metabolic bone diseases like osteoporosis or Paget's disease.
• Electrolyte Imbalance: Because Scandium interacts with calcium-binding proteins, there is a theoretical risk of disrupting calcium signaling. Patients with pre-existing hypocalcemia (low blood calcium) should be treated with caution.

If you are receiving Scandium for diagnostic purposes, your doctor may order the following tests:

• Renal Function Tests: Blood Urea Nitrogen (BUN) and Serum Creatinine to ensure the kidneys can clear the agent.
• Serum Electrolytes: To monitor calcium, magnesium, and phosphate levels.
• Complete Blood Count (CBC): To check for any unusual immune responses following administration.
• Follow-up Imaging: To ensure the tracer has cleared the target organs as expected.

Scandium itself does not typically cause sedation or cognitive impairment. However, some patients may experience transient dizziness or nausea following an injection. It is recommended to wait at least 30 to 60 minutes after the procedure before driving to ensure you do not experience any delayed reactions.

There are no direct chemical interactions between Scandium and alcohol. However, alcohol can cause dehydration, which may put additional strain on the kidneys as they work to clear the Scandium from your system. It is best to avoid alcohol for 24 hours before and after a Scandium-based diagnostic procedure.

Since Scandium is usually administered as a single dose or a short course for testing, there is no risk of a 'withdrawal syndrome.' There is no need for tapering. However, if you are undergoing a series of tests and decide to stop, the diagnostic information may be incomplete, which could affect your overall treatment plan.

> Important: Discuss all your medical conditions, especially any history of kidney disease or metal allergies, with your healthcare provider before starting any procedure involving Scandium.

Scandium should not be used in combination with certain other agents due to the risk of severe reactions or diagnostic interference:

• Other Rare Earth Contrast Agents: Using Scandium simultaneously with Gadolinium-based contrast agents can overwhelm the renal clearance pathways and increase the risk of Nephrogenic Systemic Fibrosis (NSF).
• Strong Chelating Agents: Medications like EDTA or Penicillamine, which are used to treat metal poisoning, will bind to Scandium and remove it from the body. This would render a diagnostic Scandium tracer useless.

• Calcium Channel Blockers (CCBs): Since Scandium is a Calcium [EPC], it may theoretically interfere with the action of CCBs like Amlodipine or Verapamil. While not strictly forbidden, patients on high-dose CCBs should be monitored for changes in blood pressure or heart rate during Scandium administration.
• Bisphosphonates: These bone-strengthening drugs (like Alendronate) change bone turnover rates. Since Scandium is a bone-seeking element, bisphosphonates may alter the distribution and clearance of Scandium, potentially affecting diagnostic accuracy.

• Diuretics (Water Pills): Drugs like Furosemide or Hydrochlorothiazide affect renal excretion and electrolyte balance. They may speed up or slow down the clearance of Scandium, requiring the clinician to adjust the timing of diagnostic measurements.
• Antacids and Calcium Supplements: If Scandium is taken orally as a tracer, high doses of calcium or magnesium from antacids can compete for absorption, significantly reducing the amount of Scandium that enters the bloodstream.

• High-Phytate Foods: Foods like whole grains, legumes, and nuts contain phytates that can bind to trivalent metals like Scandium in the gut, preventing their absorption. If taking an oral Scandium tracer, these foods should be avoided for several hours before and after the dose.
• Dairy Products: High calcium content in milk and cheese can compete with Scandium for the same uptake transporters in the intestines.

• Phytic Acid/IP-6 Supplements: These will bind Scandium and prevent its absorption or utilization as a tracer.
• Vitamin D: By increasing calcium absorption and bone turnover, Vitamin D supplements may indirectly affect how Scandium is distributed in the body.

• Serum Calcium Tests: Scandium may interfere with certain colorimetric assays used to measure blood calcium levels, leading to a falsely high or low reading. Always inform the laboratory if you have recently received a Scandium-based agent.
• Bone Scans: If you are undergoing a traditional Technetium-99m bone scan, recent administration of Scandium may interfere with the uptake of the radioactive tracer into the bone.

> Important: Tell your doctor about ALL medications, supplements, and herbal products you are taking, including any recent diagnostic tests involving contrast dyes or radioactive tracers.

Scandium must NEVER be used in the following circumstances:

• Severe Renal Failure (GFR < 30 mL/min): Patients with end-stage renal disease cannot effectively clear Scandium. This leads to a high risk of systemic accumulation and potential heavy metal toxicity.
• Known Hypersensitivity to Scandium or Lanthanides: If a patient has had a previous anaphylactic or severe allergic reaction to Scandium Iodide or related rare earth elements (like Yttrium or Lanthanum), they must not receive it again.
• Pregnancy (for radioactive isotopes): Radioactive forms of Scandium are absolutely contraindicated during pregnancy due to the risk of fetal radiation exposure and potential teratogenic effects.

In these cases, a healthcare provider will perform a careful risk-benefit analysis:

• Moderate Renal Impairment: Requires significant dose reduction and post-procedure monitoring.
• Metabolic Bone Disease: Conditions like Osteogenesis Imperfecta or severe Osteoporosis may alter how Scandium is deposited in the body, potentially leading to inaccurate diagnostic results or localized bone irritation.
• Pre-existing Electrolyte Imbalance: Particularly severe hypocalcemia or hypercalcemia, as Scandium's interaction with calcium-binding sites could exacerbate these conditions.

There is a known risk of cross-sensitivity between Scandium and other transition metals or lanthanides. Patients who are allergic to Gadolinium (often used in MRI contrast) or Lanthanum (used as a phosphate binder) may be at an increased risk of an allergic reaction to Scandium Iodide. A skin prick test or a small 'test dose' may be required if cross-sensitivity is suspected.

> Important: Your healthcare provider will evaluate your complete medical history, including any history of kidney disease or previous reactions to medical dyes, before prescribing or administering Scandium.

Scandium is generally classified in Pregnancy Category C. This means that animal reproduction studies have shown an adverse effect on the fetus, and there are no adequate and well-controlled studies in humans, but potential benefits may warrant use of the drug in pregnant women despite potential risks. However, if the Scandium is in a radioactive form, it is strictly contraindicated. For non-radioactive Scandium Iodide, it should only be used if the diagnostic information is critical for the mother's health and cannot be obtained through other means. There is a theoretical risk that Scandium could cross the placenta and interfere with the developing fetal skeleton.

It is not known whether Scandium is excreted in human milk. However, many trivalent metals do pass into breast milk in small quantities. Because the effects of Scandium on a nursing infant are unknown, healthcare providers often recommend interrupting breastfeeding for 24 to 48 hours following the administration of a Scandium-based diagnostic agent. During this time, the mother may 'pump and dump' to maintain supply while ensuring the infant is not exposed to the metal.

Scandium is not FDA-approved for routine use in children. Its use in pediatric populations is limited to highly specialized research or diagnostic scenarios. The primary concern is the incorporation of Scandium into the rapidly growing bone matrix of children. Long-term studies on the effects of rare earth metal deposition in pediatric bone are lacking. If used, dosing must be meticulously calculated based on weight and age.

Elderly patients are at a higher risk for adverse effects from Scandium, primarily due to the age-related decline in renal function. Clinical studies of diagnostic agents often include fewer patients over 65, but general medical practice dictates using the lowest effective dose. Geriatric patients should also be monitored for dizziness or falls following administration, as they may be more sensitive to transient blood pressure changes or lightheadedness.

Renal impairment is the most significant factor in Scandium safety.

• Mild Impairment (GFR 60-89): No adjustment usually needed, but monitor hydration.
• Moderate Impairment (GFR 30-59): Reduce dose by 25-50% and monitor serum creatinine post-procedure.
• Severe Impairment (GFR < 30): Use is generally avoided unless no alternative exists.

Standard hepatic impairment (Child-Pugh Class A, B, or C) does not significantly alter the clearance of Scandium, as the liver is not the primary organ of elimination. However, patients with advanced liver disease often have secondary kidney issues, so renal function must still be the primary focus of safety assessments.

> Important: Special populations require individualized medical assessment. Always inform your specialist if you are pregnant, planning to become pregnant, or breastfeeding before receiving Scandium.

Scandium Iodide ($ScI_3$) functions primarily as a calcium biomimetic. At the molecular level, the $Sc^{3+}$ ion has an ionic radius of approximately 74.5 pm, which is comparable to the $Ca^{2+}$ ion (100 pm) but with a higher charge density. This allows Scandium to bind with high affinity to calcium-binding proteins such as calmodulin, troponin C, and parvalbumin. In many cases, Scandium binds even more tightly than calcium, effectively 'locking' the protein in a specific conformation. This property is exploited in diagnostic tracing to label specific calcium-dependent pathways. In the context of its classification as an allergen, the $Sc^{3+}$ ion acts as a hapten, binding to skin proteins to form a complex that is recognized by T-cells, triggering an immune response in sensitized individuals.

The pharmacodynamic effect of Scandium is dose-dependent. In diagnostic doses (micrograms), there is no observable physiological effect on the patient's heart rate, blood pressure, or muscle contraction. However, at toxicological levels, the displacement of calcium could theoretically lead to impaired muscle contraction and altered nerve conduction. The onset of action for a Scandium tracer is immediate upon intravenous injection, with peak diagnostic concentrations in the blood occurring within minutes.

| Parameter | Value |

|---|---|

| Bioavailability | <5% (Oral), 100% (IV) |

| Protein Binding | 70-85% (primarily Albumin) |

| Half-life | 2-6 hours (Initial), 50+ hours (Terminal) |

| Tmax | 0.5 - 1.5 hours (Oral) |

| Metabolism | None (Elemental) |

| Excretion | Renal 80%, Fecal 20% (after IV) |

• Molecular Formula: $ScI_3$ (Scandium Iodide)
• Molecular Weight: 425.67 g/mol
• Solubility: Highly soluble in water and ethanol.
• Structure: In its solid state, Scandium Iodide forms a crystal lattice. In solution, it dissociates into one $Sc^{3+}$ ion and three $I^-$ ions.

Scandium is classified as a rare earth transition metal. In the medical regulatory framework, it belongs to the Calcium [EPC] class due to its ionic mimicry and the Standardized Chemical Allergen [EPC] class due to its use in immunological testing. It is related to other diagnostic metals like Gadolinium and Yttrium.